Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider’s healthcare editor Lydia Ramsey Pflanzer. Subscribe here to get this newsletter in your inbox every weekday.
Happy Tuesday! Today, a look at what’s inside Congress’s next coronavirus stimulus bill, a plant-based coronavirus vaccine makes it into human testing, and a look at the downfall of Civilized, a cannabis media startup.
Alex Wong/Getty Images
From stimulus checks to unemployment benefits, top analysts shared their predictions for the next coronavirus bailout package. They’re pegging it at $1.5 trillion.
- Congress and the Trump administration are negotiating another coronavirus stimulus bill.
- Top analysts told us the legislation will spend $1.5 trillion in all.
- As part of it, analysts say they expect the next coronavirus bailout to blend unemployment payments and back-to-work bonuses.
- Here’s what’s expected in the next bill.
The Canadian biotech Medicago is betting it can make a coronavirus vaccine out of plants, and it just started testing it in humans
- Among the more than 150 research programs working to develop a coronavirus vaccine, Medicago stands out with its plant-focused approach.
- Medicago developed its vaccine using a unique approach that turns the cells of a tobacco-like crop into protein-producing minifactories, CEO Bruce Clark told Business Insider.
- On Tuesday, the privately held Canadian drugmaker started testing its vaccine candidate in humans.
The inside story of the downfall of Civilized, a cannabis media startup that raised $7 million, then had to shut down after a takeover offer fell through
- Civilized and its husband-and-wife founders were soaring as cannabis legalization looked poised to sweep the US a few years ago.
- But after a series of layoffs and business pivots, as well as a failed takeover attempt, Civilized has let go of all of its staff and suspended operations.
- Civilized’s management team told Business Insider they were in negotiations to restructure their debt and bring on new investors for a relaunch.
More stories we’re reading:
- The CDC’s apolitical stance made it vulnerable to President Trump (Stat News)
- WHO: We won’t immediately have a ‘perfect vaccine,’ and it is ‘not realistic’ to expect the virus will soon be eliminated (Business Insider)
- Drugmaker Biocon got approved to use its drug itolizumab to treat coronavirus patients in India (Reuters)
- Moderna surges 18% on report the stock will join the Nasdaq 100 and as analyst predicts 45% upside (Markets Insider)
What trends in healthcare are you keeping an eye on? Let me know at firstname.lastname@example.org.
The Most Powerful Sale & Affiliate Platform Available!
There's no credit card required! No fees ever.Create Your Free Account Now!
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe